Overview
Legal name
HYPER UNISON LTD
Region
London
Registered address
128 CITY ROAD
LONDON
UNITED KINGDOM
EC1V 2NX
Insolvency history
No
Company
Active
LTD
Company profile
Hyper Unison Ltd
Unison: Genomics and Microbiome Data Platform
Genomics and microbiome data for early stage drug discovery
CRN
14209776
Founded
2022
Age
4
Latest accounts
Financial period: 1 Aug 2023 to 31 Jul 2024
FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
1
Company events
Reference milestones and recent Companies House filing stream events.
7 events
17 Sep
2026
Confirmation statement due
Confirmation DueNext confirmation statement due date
08 Jul
2026
Gazette Filings Brought Up To Date
GazetteDISS40 | Transaction MzUzMDk4ODIzMGFkaXF6a2N4 | Paper/PDF filed
Published 08 Jul 2026 23:01
23 Jun
2026
Gazette Notice Compulsory
GazetteGAZ1 | Transaction MzUyODY3ODMwMWFkaXF6a2N4 | Paper/PDF filed
Published 01 Jul 2026 02:25
30 Apr
2026
Accounts due
Accounts DueNext accounts due date
03 Sep
2025
Confirmation statement filed
ConfirmationLast confirmation statement made up date
31 Jul
2024
Accounts filed
AccountsLast accounts made up date
01 Jul
2022
Incorporated
InceptionCompany registered at Companies House
Public funding
1 award
First funded
2023
Funded years
2023
Age at first award
1 years
Projects
2023
Collaborative R&D
An integrated approach to Alzheimer's Disease diagnostics harnessing liquid biopsies and combination AI modeling
1 Dec 2023 to 30 Jun 2025
Awarded
£65,791
Total cost £93,987
CFDX is a UK-based precision medicine SME collaborating with Unison, a UK-based secure healthcare data infrastructure developer. CFDX's main team is composed of Dr. Ravi Solanki (Project Lead), Dr. Jonathan Wan (Technical Lead), and Hannah Thompson (Clinical Operations). Additional partnerships have also been established with Dr. Ivan Koychev, the Chief I...
Product types
Collaborative R&D